Posted , 6 users are following.
The case for adopting GreenLight XPS for treating benign prostatic hyperplasia is supported in non-high-risk patients. Please see the guidance for details.
We estimate that around 13,600 people with benign prostatic hyperplasia are eligible to have GreenLight XPS. Uptake of GreenLight XPS will be steady from year 2 onwards with around 6,800 people having the procedure each year.
Savings range from £1.3 million when 36% of procedures with GreenLight XPS are done as day cases, to as much as £3.2 million when 70% are done as day cases.
Based on 53% of GreenLight XPS procedures being done as day cases, the guidance is estimated to save the NHS around £2.3 million per year (or £4,200 per 100,000 people
0 likes, 26 replies